Clinical Trials Logo

Cognitive Dysfunction clinical trials

View clinical trials related to Cognitive Dysfunction.

Filter by:
  • Terminated  
  • « Prev · Page 11

NCT ID: NCT00675025 Terminated - Down Syndrome Clinical Trials

Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial

Start date: April 4, 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety of donepezil hydrochloride (Aricept) in children with Down syndrome who have finished the preceding 10-week, double-blind study of donepezil hydrochloride. Medical tests for drug safety will be conducted at each clinic visit.

NCT ID: NCT00597545 Terminated - Diabetes Clinical Trials

Effect of Raised CBF During CEA on Cognition in DM Patients

Start date: March 2007
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if we can reduce the incidence of cognitive dysfunction — difficulty in performing certain pencil-paper, memory, finger dexterity and thinking type of tasks called neuropsychometric tests — in patients with adult onset diabetes mellitus (DM) undergoing surgery on the carotid artery (CEA). We hypothesize that cognitive dysfunction can be decreased in patients with type II DM by augmenting cerebral blood flow with a shunt during carotid endarterectomy compared to patients with Type II DM who are treated with "conventional" management in which a shunt is placed only if the electroencephalogram (EEG) indicates cerebral ischemia.

NCT ID: NCT00455143 Terminated - Clinical trials for Postoperative Delirium

Cognitive Protection - Dexmedetomidine and Cognitive Reserve

Start date: September 2006
Phase: Phase 4
Study type: Interventional

This is a pilot study to evaluate the effect of dexmedetomidine in the prevention of delirium in non-cardiac surgical patients. The preliminary data regarding the effect of dexmedetomidine on delirium comes from a study underway at Stanford. We propose to randomize fifty patients into two different protocols, one using dexmedetomidine until PACU discharge (hip replacement) and the other using dexmedetomidine for 24 hours in a monitored setting.

NCT ID: NCT00202540 Terminated - Clinical trials for Mild Cognitive Impairment

Efficacy and Safety of S18986 in the Treatment of Mild Cognitive Impairment Patients

Start date: June 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to demonstrate a long term efficacy of S18986 versus placebo on episodic memory performance in patients with MCI

NCT ID: NCT00148616 Terminated - Clinical trials for Chronic Schizophrenia

Memantine for the Treatment of Cognitive Dysfunction and Negative Symptoms in Patients With Chronic Schizophrenia

Start date: April 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of 24 weeks memantine add-on treatment to risperidone for the treatment of negative symptomatology and cognitive impairment in patients with chronic schizophrenia.

NCT ID: NCT00148590 Terminated - Schizophrenia Clinical Trials

Memantine for the Prevention of Cognitive Dysfunction and Negative Symptoms in Patients With Acute Schizophrenia

Start date: November 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of a 6 weeks memantine add-on to risperidon treatment for the prevention of cognitive dysfunction and negative symptomatology in patients with acute schizophrenia. Psychopathological changes were assessed with the Positive and Negative Syndrome Scale (PANSS) at baseline and after 2, 4, 6, 12, and 24 weeks. Cognitive function were measured at baseline and week 6, and 24 by the California Verbal Learning Test, Benton Learning Test, Digit Span Forward and Backward Test, Continuous Performance Test, Stroop Test, Trail-Making Test, Verbal Fluency Test, and Wisconsin Card Sorting Test.